Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): A randomized clinical trial in dogs with mammary carcinoma

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 1015-1019

  Teske, Erik ^a   Rutteman, Gerard R ^a   V D Ingh, Ted S G A M ^a   Van Noort, Ronald ^a   Misdorp, Wim ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Dog; Immunotherapy; Liposomes; Mammary cancer; MTP PE

Indexed keywords

LIPOSOME; MURAMYL TRIPEPTIDE; PHOSPHATIDYLETHANOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DOG; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHIVERING;

EID: 0031810918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Dorn CR, Taylor DON, Schneider R, Hibbord HH and Klauber MR: Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40: 307-318, 1968.
2. Owen LN: A comparative study of canine and human breast cancer. Invest Cell Pathol 2: 257-275, 1979.
3. Misdorp W and Hart AAM:Prognostic factors in canine mammary cancer. J Natl Cancer Inst 56: 779-786, 1976.
4. Lebeau A: L'age du chien et celui de l'homme: essay de statistique sur la mortalite canine. Bull Acad Vet 26: 229-232, 1953.
5. Schneider R: Comparison of age, sex and incidence rates in human and canine breast cancer. Cancer 26:439-426, 1970.
6. Hamilton JM: Comparative aspects of mammary tumors. Adv Cancer Res 19: 1-45,1974.
7. Hampe JF and Misdorp, W: Tumours and dysplasias ofthe mammary gland. Bull WHO 50: 111-133, 1974.
8. Bostock DE: Canineandfelinemammaryneoplasms. Br Vet J 142: 506, 1986.
9. MacEwen EG: Current concepts in cancer therapy: biologic therapy and chemotherapy. Sem Vet Med Surg 1: 5-16, 1986.
10. Fidler IJ, Brodey RS and Bech-Nielsen S: In vitro immune stimulation-inhibition to spontaneous canine tumors of various histologic types. J Immunol 112: 3, 1974.
11. Owen LN, Lewis JCM, Morgan DR and Gorman NT: The effects of Corynebacterium parvum in dogs and a study of its distribution following intravenous injection. Eur J Cancer 16: 999-1005, 1980.
12. Sedlacek HH, Hagmayer G and Seiler FR: Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Cancer Immunol Immunother 23: 192-199, 1986.
13. Bostock DE and Gorman NT: Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision ofthe primary tumor. Eur J Cancer 14: 879-883, 1978.
14. Rutten VP, Misdorp W, Gauthier A, Estrada M, Mialot JP, Parodi AL, Rutteman GR and Weyer K: Immunological aspects of mammary tumors in dogs and cats: a survey including own studies and pertinent literature. Vet Immunol Immunopathol 26: 211-225, 1990.
15. Parodi AL, Misdorp W,Mialot JP, Mialot M, Hart AAM, Hurtrel M and Salomon JC: Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy. Cancer Immunol Immunother 15: 172-177, 1983.
16. Withworth PW, Pak CC, Esgro J, Kleinerman ES and Fidler IZ: Macrophages and cancer. Cancer Metast Rev 8: 319-351, 1990.
17. Sane S and Fidler IJ: in vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol 57: 42-50, 1981.
18. Fidler IJ, Sone S, Fogler WE and Barnes ZL: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78: 1680-1684, 1981.
19. Fidler IJ: Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol Immunother 21: 169-173, 1986.
20. Paste G, Kirsh R and Fidler IJ: Cell surface receptors for lymphokines. Cell Immunol 44: 71-88, 1979.
21. Schroit AJ and Fidler IJ: Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 42: 161, 1982.
22. MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK and Howard PE: Therapy for osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. J NatlCancer Inst 81: 935-938, 1989.
23. MacEwen EG, Kurzman ID, Helfland S, Vail D, London C, Kisseberth W, Rosenthal RC, Fox LE, Keller ET, Obradovich J et al: Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target 2: 391-396, 1994.
24. Kleinerman ES, Maeda M and Jaffe N: Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res 62: 101-107, 1993.
25. Norusis MJ, SPSS Inc. SPSS for Windows. Base system user's guide release 5.0, Chicago, SPSS, 1992.
26. EGRET. User's manual. Statistics and Epidemiologic Research Cooperation, Seattle, Washington, 1989.
27. Fidler IJ and Schroit AJ: Recognition and destruction of neoplastic cells by activated macrophages: Discrimination of altered self Biochim Biophys Acta 948: 151 -173, 1988.
28. Fidler IJ: Immunomodulation of macrophages for cancer and antiviral therapy. In: Tomlinson E, Davis SS (Eds), Site-specific drug delivery. John Wiley and Sons, New York, 111-135, 1986.
29. Smith BW, Kurzman ID, Schultz KT, Czuprynski CJ and MacEwen EG: Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. Cancer Biother 8 137-144, 1993.
30. Kurzman ID, Shi F and MacEwen EG: in vitro and in vivo canine mononuclear cell production oftumor necrosis factor induced by muramyl peptides and lipopolysaccharide. Vet Immunol Immunopathol 38: 45-56, 1993.
31. Shi F, Kurzman ID and MacEwen EG: in vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs. Cancer Biother 10: 317-325, 1995.
32. Fox LE, King RR, Shi F, Kurzman ID, MacEwen EG and Kubilis PS: Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphati-dylethanolamine (L-MTP-PE) in normal cats. Cancer Biother 9: 329-340, 1994.
33. Frost H, Murray JL, Chaudri HA and Van Damme J.: Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. J Biol Resp Modif 9: 160-166, 1990.
34. Landmann R, Obrist R, Denz H, Ludwig C, Frost H, Wesp M, Rordorf C, Towbin H, Gygax D, Tarcsay L: Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. Biotherapy 7: 1-12, 1993.
35. Verweij J, Judson I Steward W, Coleman R, Woll P, Van Ponelsberghe C, Van Glabbeke M and Moridsen H: Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. Eur J Cancer 30A: 842-843, 1994.
36. Asano T and Kleinerman ES: Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother 14: 286-292, 1993.
37. Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R and Fidler IJ: Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother 34: 211-220, 1992.
38. Fox LE, MacEwen EG, Kurzman ID, Dubielzig RR, Helfland SC, Vail DM, Kisseberth W, London C, Madewell BR, Rodriguez CO Jr et al: Liposome encapsulated muramyl tripeptide phosphati-dylethanolamine for the treatment of feline mammary adenocarcinoma-a multicenter randomized double-blind study. Cancer Biother 10: 125-130, 1995.
39. London CA, MacEwen EG, Kurzman ID and Vail DM: Distribution of metastasis in dogs with appendicular osteosarcoma receiving liposome encapsulated muramyl tripeptide phosphatidyl-ethanolamine (L-MTP-PE). Proceedings Veterinary Cancer Society, 46-47, 1996.